Ajanta Pharma Limited (BOM:532331)
India · Delayed Price · Currency is INR 3,012.15
+42.15 (1.42%)
At close: Jun 9, 2026
Ajanta Pharma Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Ajanta Pharma stock has a consensus rating of "Strong Buy" and an average price target of ₹3,303. The average 1-year stock price forecast is 9.67% higher than the current stock price, while the lowest is ₹2,605 (-13.52%) and the highest is ₹3,829 (+27.12%).
Price Target: ₹3,303 (+9.67%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ajanta Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 9 | 11 | 11 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 2 | 2 | 2 | 2 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 12 | 12 | 12 | 13 | 13 |
Financial Forecast
Revenue This Year
62.67B
from 54.53B
Increased by 14.93%
Revenue Next Year
70.33B
from 62.67B
Increased by 12.22%
EPS This Year
98.31
from 84.51
Increased by 16.33%
EPS Next Year
113.89
from 98.31
Increased by 15.85%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 64.4B | ||
| Avg | 62.7B | ||
| Low | 60.1B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 18.1% | ||
| Avg | 14.9% | ||
| Low | 10.2% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 102.90 | ||
| Avg | 98.31 | ||
| Low | 93.73 |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 21.8% | ||
| Avg | 16.3% | ||
| Low | 10.9% |